Overall verdict
Neutral
6.0/10
1-year performance
-28.73%
Score breakdown
Down 28.7% over 1 year, 2% of the 52-week range.
Strongest: Financial strength 10.0/10. Weakest: Growth 4.1/10.
8 analysts, target +1.2% vs the price.
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders ; SCENESSE and other formulations of afamelanotide to treat severe disorders, including vitiligo and porphyrias ;
and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Sector
Health Care
Industry
Biotechnology
Primary listing
Asx
Australia
CEO
Philippe Wolgen
Founded
1999
Employees
—
Revenue / employee
—
Next earnings
—
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
13.48 AUD
52-week low
7.93 AUD
1-year performance
-28.73%
Declining
Year-to-date performance
-33.97%
Declining
Drawdown
-40.50%
Major drawdown
Position in the 52-week range
2% of range
Range: 16.13 AUD - 16.97 AUD (3 methods agree)
The price implies growth of -1.89% per year; the company grows at 6.69%.
Gross margin 82.1%, net margin 36.1%, ROIC 13.2%, ROE 13.2%.
Net margin
36.07%
Exceptional
Sector -229.34%|S&P 12.97%
Gross margin
82.13%
Exceptional
Return on equity (ROE)
13.21%
Fair
Sector -58.37%|S&P 16.52%
Return on invested capital (ROIC)
13.16%
Fair
Free cash flow margin (FCF)
37.55%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.04x
Exceptional
Margin stability
5.9 pts
Uneven
Revenue to net income
Growth
4.1/10Revenue down 3.8% over 1 year, 14.4% a year over 5, EPS 6.7% a year over 5.
Revenue (trailing 12 months)
94.0M AUD
Revenue growth (1y)
-3.80%
Declining
Revenue growth (3y)
20.05%
Solid
EPS growth (1y)
5.30%
Moderate
EPS CAGR (5y)
6.69%
Exceptional
EPS revisions (3 months)
-10.99%
Sharply revised down
Valuation
5.7/10P/E 12.0x, forward P/E 11.3x, EV/EBITDA 4.0x, PEG 1.79. The multiple sits in the 3th percentile of its own 5-year history.
P/E (TTM)
12.0x
Fair
Sector 11.2x|S&P 23.0x
Forward P/E
11.3x
Expensive
EV / EBITDA
4.0x
Cheap
Sector 13.5x|S&P 14.5x
PEG
1.79
Expensive
Sector 1.05|S&P 0.86
Fair value (reverse DCF)
16.55 AUD
Deeply undervalued
P/E vs its own 5-year history
among the 3% lowest valuations
Far cheaper than usual
Market cap
419M AUD
Financial strength
10.0/10Cash covers 13002.7% of the debt, net debt/EBITDA -6.0x.
Net debt / EBITDA
-6.0x
Net cash
Gearing (net debt / equity)
-91.66%
Net cash
Cash
252M AUD
Cash / market cap
60.20%
Very solid
Cash / total debt
13002.69%
Net cash
Net debt
-250M AUD
Equity
273M AUD
Closed daily candles, 2 years
Last close on September 24, 2026: 8.26 AUD
- MM208.22
- MM509.18
- MM20010.12
- RSI 1441.2
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-3.28%
200-day average slope, 3 months
-6.35%
50-day average slope, 1 month
-8.14%
Price structure
Lower lows
Bullish RSI divergence
Yes
20-day volatility
2.55 % per day
Volatility change
+11.79%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2027 | 0.71 (6) | 0.70 (7) | 95 (6) | 38 (6) | 36 (6) |
Amounts in millions of AUD, EPS in AUD per share. In brackets, the number of analysts. Consensus as of September 8, 2026.
Same sub-industry: 734 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RCKT | 6.8 | N/A | 332M USD | Not meaningful (loss) | — | — | -4.5 % | 1.4x | -51.4 % | -14.6 % | ||
| 2 | CUV | 6.0 | 6.3 | 294M USD | 12.0x | 36.1 % | -3.8 % | 13.2 % | -6.0x | 8.4 % | -28.7 % | ||
| 3 | XFOR | 4.9 | 2.5 | 308M USD | Not meaningful (loss) | -568.8 % | 346.3 % | -57.6 % | 1.5x | — | -13.3 % | ||
| 4 | IKT | 4.4 | 0.9 | 300M USD | Not meaningful (loss) | — | — | -52.0 % | 2.4x | -14.2 % | 29.6 % | ||
| 5 | CATX | 4.4 | 1.6 | 299M USD | Not meaningful (loss) | -28516.1 % | -72.1 % | -39.2 % | 2.1x | -40.6 % | -21.4 % | ||
| 6 | SANN | 4.0 | 3.5 | 286M USD | Not meaningful (loss) | -63.8 % | 97.3 % | -62.8 % | -2.3x | -15.4 % | 25.2 % | ||
| 7 | ALERS | 3.6 | 4.1 | 287M USD | 51.9x | 2.9 % | 9.1 % | 2.6 % | -0.1x | 1.9 % | -1.4 % | ||
| 8 | AMRN | 3.3 | 3.7 | 290M USD | Not meaningful (loss) | -14.6 % | -42.6 % | -5.9 % | 14.7x | 5.4 % | -12.0 % | ||
| 9 | A174900 | 2.1 | 2.2 | 285M USD | Not meaningful (loss) | -328.3 % | 51.4 % | -40.6 % | 0.2x | -3.1 % | 27.3 % |
